The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease
Clicks: 11
ID: 306398
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
3.0
/100
11 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #11 of 18 articles by views in Journal of Crohn s and Colitis
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
This is the first European Crohn’s and Colitis Organisation [ECCO] consensus guideline that addresses extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD]. It has been drafted by 21 ECCO members from 13 European countries. Although this is the first ECCO consensus guideline that primarily addresses EIMs, it is partly derived from, updates, and replaces previous ECCO consensus advice on EIMs, contained within the consensus guidelines for Crohn’s disease1 [CD] and ulcerative colitis2 [UC]. The strategy to define consensus was similar to that previously described in other ECCO consensus guidelines [available at www.ecco-ibd.eu]. Briefly, topics were selected by the ECCO guidelines committee [GuiCom]. ECCO members were selected to form working groups. Provisional ECCO Statements and supporting text were written following a comprehensive literature review, then refined following two voting rounds which included national representative participation by ECCO’s 35 member countries. The level of evidence was graded according to the Oxford Centre for Evidence-based Medicine [www.cebm.net]. The ECCO Statements were finalised by the authors at a meeting in Vienna in October 2014 and represent consensus with agreement of at least 80% of participants. Complete consensus [100% agreement] was reached for most statements. The supporting text was then finalised under the direction of each working group leader [VA, SV, FC, MH] before being integrated by the two consensus leaders [MH, FC]. This consensus guideline is pictorially represented within the freely available ECCO e-Guide [http://www.e-guide.ecco-ibd.eu/].
Up to 50% of patients with inflammatory bowel disease [IBD] experience at least one extra-intestinal manifestation [EIM], which can present before IBD is diagnosed.34,5,6 EIMs adversely impact upon patients’ quality of life and some, such as primary sclerosing cholangitis [PSC] or venous thromboembolism [VTE], can be life-threatening. The probability of developing EIMs increases with disease duration and in patients who already have one EIM.7 …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (299 words).
Try re-searching for a better abstract.
| Reference Key |
openalex_W2177651241
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Marcus Harbord, Vito Annese, Stephan R. Vavricka, Matthieu Allez, Manuel Barreiro‐de Acosta, Kirsten Muri Boberg, Johan Burisch, Martine De Vos, Annemarie de Vries, Andrew D. Dick, Pascal Juillerat, Tom H. Karlsen, Ioannis E. Κoutroubakis, Péter L. Lakatos, Tim Orchard, Pavol Papay, Tim Raine, Max Reinshagen, Diamant Thaçi, Herbert Tilg, Franck Carbonnel |
| Journal | Journal of Crohn s and Colitis |
| Year | 2015 |
| DOI |
10.1093/ecco-jcc/jjv213
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.